Navigation Links
Interventional Pulmonology Creeping into Bronchoscopy Market
Date:4/7/2008

Interventional Pulmonology is expected to increase the bronchoscopy market to approximately $180 million in 2012, according to Millennium Research

Group

WALTHAM, Mass., April 7, 2008 /PRNewswire/ -- According to Millennium Research Group's US Markets for ENT & Bronchoscopy 2008 report, an emerging field -- interventional pulmonology -- is creeping into the bronchoscopy market, and is expected to grow the overall market to $180 million by 2012.

To date, the majority of bronchoscopy procedures have been performed to diagnose pulmonary conditions such as lung cancer and chronic lung disease. A number of medical devices that can be used to treat lung-related conditions are, however, awaiting FDA approval. If these therapeutic devices are approved, bronchoscopy procedure volumes in the US will expand as pulmonologists and thoracic surgeons gain the ability to both diagnose and treat lung-related conditions using minimally invasive techniques. Because many interventional pulmonology procedures will be performed with a flexible bronchoscope, therapeutic device approval will also fuel demand for flexible bronchoscopes and other conventional bronchoscopy devices.

Asthmatx' Alair System, which was developed to treat severe asthma cases, will be submitted for FDA premarket approval in 2008. Its approval will add bronchial thermoplasty to the list of treatments that can be performed with flexible bronchoscopy.

"To date, clinical studies performed with the system have showed favorable results," says Tiffanie Demone, Analyst at Millennium Research Group. "A study published in the New England Journal of Medicine in March 2007 found that patients who underwent a bronchial thermoplasty used less rescue medication such as that found in inhalers and showed improvements to their quality of life. Moreover, there were almost 2.5 million severe asthma patients in the US in 2007 who could potentially benefit from bronchial thermoplasty."

The US Markets for ENT & Bronchoscopy 2008 report provides coverage of key industry competitors, including Arthrocare, Boston Scientific, Medtronic, and Olympus.

About Interventional Pulmonology

Interventional pulmonology is the treatment of breathing-related disorders such as asthma, lung cancer, chronic obstructive pulmonary disease, and emphysema. Paralleling the interventional cardiology market in the 1980s, the development of interventional pulmonology is changing the role of a pulmonologist from diagnostician to therapeutic interventionalist. A number of interventional pulmonology device developers formed over the last few years, including Emphasys Medical, Asthmatx, Spiration, Pulmonx, PneumRx, and superDimension. The approval and adoption of medical devices developed by these companies will expand the interventional pulmonology market in the coming years.

About Millennium Research Group

Millennium Research Group (http://www.MRG.net), a Decision Resources, Inc. company (http://www.DecisionResources.com), is the global authority on medical technology market intelligence and a leading provider of strategic information to the health care sector. Focused solely on the medical device, pharmaceutical, and biotechnology industries, the company provides its clients with the benefits of its specialized industry expertise through published reports and customized consulting services.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Amy Krohn

Millennium Research Group

416-364-7776 x101

akrohn@mrg.net


'/>"/>
SOURCE Millennium Research Group
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. See More, Do More: Siemens Highlights New Generation of Interventional Imaging Systems for Cardiology at ACC
2. Safe at Any Age: Octogenarians Do As Well as Younger Patients With Interventional Radiology Arterial Procedures
3. New Interventional Radiology Treatment Shows Hope for People With Complications from Bone Marrow, Stem Cell Transplants
4. Register Now for Interventional Radiology Meeting Press Conferences
5. SCAI Announces New Program to Support Interventional Cardiology Training Fellowships
6. Siemens Introduces Its New Generation of Artis Interventional Imaging Systems
7. Stereotaxis Showcases Interventional Cardiology Capabilities of Niobe Magnetic Navigation System
8. Gorilla Receives State-Of-The-Art Treatment for Uterine Fibroids from Interventional Radiologists
9. SCAI and ACC announce new interventional cardiology meeting
10. Stereotaxis Appoints Senior Vice President of Global Marketing and General Manager for Europe
11. Biopure Receives Comment Letter From U.K. Regulatory Body on Marketing Application for Hemopure(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
(Date:6/24/2016)... Norcross, Georgia (PRWEB) , ... June 24, 2016 ... ... Year” awards today at the Clinical Decision Making in Emergency Medicine conference in ... who have authored journal articles published in Emergency Medicine Practice and ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... The Grove Investment Group (TGIG), has initiated cultivation and processing operations at its ... Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the placement ... Vice President of North American Capital Sales at HTG Molecular . ... in the commercialization of the HTG EdgeSeq system and associated reagents in North America. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, ... stem (iPS) cells and other difficult to transfect cells, announces its launch of ... PluriQ™ G9™ Gene Editing System is a complete system for culturing and ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... Ill. and INDIANAPOLIS , ... students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is ... 2016 scholarship winners, announced today online at www.diabetesscholars.org ... let type 1 diabetes stand in the way of ... has supported the Foundation,s scholarship program since 2012, and ...
Breaking Medicine Technology: